Abstract

Biotechnology was used in the first generation of so-called 'GM' crops to provide growers with complimentary and sometimes alternative crop management solutions to pesticides. Selected host genes or genes identified from other plants or non-plant sources are modified or transferred to a crop plant. The new or altered protein expression resulting from these modifications confer on the plant a desired physiological trait, such as resistance to particular herbicides or insect pests. Second generation modifications provide traits such as enhanced nutritional or health-promoting characteristics that are of benefit to consumers. The commonly raised concerns about possible implications for human health are: inherent toxicity of the novel gene and their products, the potential to express novel antigenic proteins or alter levels of existing protein allergens, the potential for unintended effects resulting from alterations of host metabolic pathways or over expression of inherently toxic or pharmacologically active substances and the potential for nutrient composition in the new food occur differing significantly from a conventional counterpart. Foods produced using biotechnology are subjected to far greater levels of scrutiny than foods produced by traditional plant breeding techniques. The accepted analytical, nutritional and toxicological methods employed to support this scrutiny and to assess and assure that a 'GM' food is a safe and nutritious as its 'non-GM' counterpart are discussed. The challenges associated with identifying unintended effects in whole GM foods and the promise new (proteomics/genomic) technologies offer opposite traditional toxicity testing paradigms are appraised.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call